What Anteris Technologies does

Anteris Technologies is a structural heart medical device company developing the DurAVR Transcatheter Heart Valve (THV) System for the treatment of severe calcific aortic stenosis. The system is built around three integrated components: the DurAVR THV itself — a first-in-class, single-piece, native-shaped biomimetic valve designed to mimic healthy aortic valve performance and restore laminar blood flow; the proprietary ADAPT anti-calcification bovine tissue that has been clinically proven calcium-free for up to 10 years and used in 55,000+ patients as a cardiac/vascular patch; and the ComASUR balloon-expandable delivery system featuring commissure alignment technology and an expandable 14Fr sheath. Headline clinical outcomes include an Effective Orifice Area of ~2.1–2.2 cm², mean pressure gradients of ~8–9 mmHg, and 97–98.5% freedom from moderate or greater prosthesis-patient mismatch in matched analyses against Edwards Sapien 3.

The company is pre-revenue and currently monetizes nothing commercially; near-term economic value derives from clinical evidence generation and eventual regulatory approvals rather than device sales. Its go-to-market motion is executing the global pivotal PARADIGM trial — a randomized, head-to-head study of approximately 1,000 patients across ~85 sites in the U.S., Europe, and Canada — to support FDA and EMA submissions, with first patients treated at Copenhagen University Hospital (Oct 2025) and Montefiore Medical Center (May 2026), and French ANSM clearance secured in June 2026. Future commercial distribution is planned via direct hospital sales to cardiac centers and structural heart programs in the U.S. and Europe, with Medtronic positioned as a potential co-commercialization and manufacturing partner following its $90M strategic investment in January 2026.

Anteris is dual-listed on NASDAQ and ASX (ticker: AVR), having completed its U.S. IPO in December 2024 and a $320M aggregate capital raise in January 2026. Headcount is 101–250 with offices in Toowong/Brisbane (Australia), Geneva (Switzerland), Eagan and Brooklyn Park (Minnesota, U.S.), and Perth (Australia); a new 181,436 sq ft manufacturing facility in Brooklyn Park begins September 2026. The wholly-owned v2vmedtech subsidiary (VClip mitral/tricuspid repair program) is in transition after Anteris terminated its development agreement in April 2026 with a $400K break fee.

Name

Anteris Technologies

Legal name

Anteris Technologies Global Corp.

Website

https://anteristech.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Anteris Technologies is a pre-revenue structural heart medical device company developing the DurAVR biomimetic transcatheter heart valve system, built on its proprietary ADAPT anti-calcification tissue, for patients with severe calcific aortic stenosis, currently advancing the global pivotal PARADIGM trial.

Ownership category

akta.pro rank

Product category

Structural Heart Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Transcatheter heart valves
• Structural heart devices
• Aortic stenosis treatment
• Anti-calcification tissue
• Cardiac valve replacement

Headquarters

HQ city

Toowong

HQ country

Australia

HQ region

Oceania

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. DurAVR THV System (future): Pre-revenue company; no commercial products yet. Planning to commercialize the DurAVR Transcatheter Heart Valve System following successful completion of PARADIGM pivotal trial and regulatory approvals from FDA and EMA. Revenue expected from device sales to hospitals and cardiac centers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Anteris Technologies develops and intends to commercialize the DurAVR® Transcatheter Heart Valve System, an integrated TAVR platform comprising a first-in-class biomimetic single-piece valve made from proprietary ADAPT® anti-calcification bovine tissue and delivered via the ComASUR® balloon-expandable delivery system. The company is pre-commercial and currently generating pivotal clinical evidence through the global PARADIGM trial (approximately 1,000 patients across US, Europe, and Canada) to support FDA and EMA regulatory approvals for the treatment of severe calcific aortic stenosis.

Product overview

Anteris Technologies is a structural heart company that has developed a unified product platform centered around the DurAVR® Transcatheter Heart Valve System. The system comprises three integrated components: the DurAVR® THV (a biomimetic transcatheter heart valve made from single-piece ADAPT® anti-calcification tissue), the ADAPT® Tissue (proprietary bovine tissue proven calcium-free for up to 10 years), and the ComASUR® Delivery System (balloon-expandable delivery platform with commissure alignment). The company is conducting the PARADIGM global pivotal trial to support regulatory approvals in the US, Europe, and Canada.

Differentiator

Problem solved

Functional benefit

Brands

• DurAVR: First-in-class biomimetic transcatheter aortic heart valve designed to mimic healthy aortic valve performance
• ADAPT
• ComASUR

Products and services

• DurAVR® Transcatheter Heart Valve (THV)

Quantifiable outcome

• Effective Orifice Area (EOA) of 2.1-2.2 cm2 sustained to 1 year, significantly larger than typical TAVR devices
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• v2vmedtech, inc.minorStrategic or Co-development Partner · 29 April 2026Anteris terminated its development agreement with v2vmedtech, inc. (a related party through shared leadership including CEO Wayne Paterson as Chair and CFO Matthew McDonnell as CFO). The agreement originally dated April 18, 2023 was in Stage 2 of development. Termination required a $400,000 break fee payment. v2vmedtech's initial shareholders retain the right to either acquire Anteris's equity interest in full or reduce it to a capped minority ownership percentage.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Edwards Lifesciences: Edwards Lifesciences is the global market leader in TAVR with the Sapien platform (Sapien 3, Sapien X4) — directly comparable to Anteris as the benchmark comparator in the PARADIGM trial. Matched analyses have shown DurAVR achieving superior hemodynamics versus Edwards Sapien 3.
• Medtronic: Medtronic's Evolut TAVR platform is the second major incumbent in the structural heart market and the strategic investor behind Anteris's $90M placement. It is the direct competitive counterpart in aortic valve replacement and a likely co-commercialization partner.
• Boston Scientific: Boston Scientific markets the Acurate neo2 TAVR valve in Europe and is expanding in structural heart. It is a direct peer competing for hospital cardiac center contracts and physician adoption in the same TAVR procedure category.

Broad incumbents

• Abbott: Abbott offers the Portico and Navitor TAVR platforms within a broader structural heart and cardiovascular portfolio. While not focused exclusively on TAVR like Anteris, it competes in the same hospital purchasing decisions and procedure volumes.

Emerging players

• JenaValve Technology: JenaValve is a privately-held TAVR developer with FDA breakthrough designation for its Trilogy device targeting aortic regurgitation and severe aortic stenosis. It is an emerging direct competitor pursuing similar differentiated indications and clinical trial pathways.
• Venus Medtech: Venus Medtech (Hangzhou) is a Chinese structural heart company developing TAVR and mitral/tricuspid technologies for global markets. It is an emerging peer pursuing similar biomimetic and durability-focused design philosophies for transcatheter valve replacement.
• 4C Medical Technologies: 4C Medical is an early-stage structural heart company developing the AltaValve system for mitral regurgitation. While focused on mitral rather than aortic, it represents the same next-generation biomimetic/transcatheter approach within structural heart.
• NeoChord: NeoChord (co-founded by Anteris Chairman John Seaberg) develops transcatheter mitral chordal repair technology. It is an adjacent structural heart peer addressing the same patient demographic of younger, lower-risk valvular disease patients via minimally invasive approaches.
• Cardiovalve: Cardiovalve (acquired by Venus Medtech) developed a transcatheter mitral and tricuspid valve replacement system. It is an emerging peer in the structural heart space targeting similar patient segments and procedural innovations as Anteris.

Regional players

• Peijia Medical: Peijia Medical is a Chinese structural heart company developing TAVR (Taurus) and transcatheter mitral/tricuspid repair devices primarily for the Asia-Pacific market. It is a regional peer with comparable technology focus but limited direct overlap with Anteris's US/European commercial focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/AnterisTech
• YouTubeyoutube.com/@anteristech
• LinkedInlinkedin.com/company/anteristech
• Facebookfacebook.com/AnterisTech

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anteris Technologies